Glaxosmithkline Share News (GSK)

LONDON MARKET OPEN: Stocks down after BoE; GSK up on Zantac settlement

(Alliance News) - Stock prices in London opened lower on Friday, as rising interest rates weighed on housebuilding stocks in the FTSE 100.

GSK reaches settlement in Goetz Zantac lawsuit

(Sharecast News) - GSK updated the market on the litigation regarding the now-discontinued heartburn drug ranitidine, or 'Zantac', on Friday.

TOP NEWS: GSK reaches settlement in California Zantac lawsuit

(Alliance News) - GSK PLC on Friday said a Zantac trial set to begin next month in California has been dismissed after it reached a confidential settlement.

Europe open: Stocks on the defensive after weak PMIs, euro awalloped

(Sharecast News) - Stocks on the Continent were trading on the back foot following the release of much weaker than expected readings for euro area factory and services activity.

LONDON BRIEFING: GSK settles Zantac litigation in California

(Alliance News) - Stocks in London are set to open in the red on Friday, as risk sentiment across the globe is damped by hawkish central banks.

European stocks head for worst week since March

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

EUROPEAN STOCKS HEAD FOR WORST WEEK SINCE MARCH (0638 GMT)

GSK says Arexvy recommended in over 60s by US CDC committee

(Alliance News) - GSK PLC on Thursday said the US Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices has voted to recommend the firm's Arexvy jab in adults aged 60 and older.

US CDC votes to recommend GSK's Arexvy against RSV

(Sharecast News) - America's public health watchdog endorsed GSK's Arexvy for use against Respiratory Syncytial Virus in adults over 60.

US CDC advisers recommend older adults may receive Pfizer, GSK shots for RSV

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections be available to older adults in the U.S. but stopped short of saying all of them should get the shots.

US CDC advisers back use of GSK, Pfizer RSV vaccines in older adults

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that adults aged 60 and above may receive the recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections. (Reporting by Raghav Mahobe in Bengaluru and Michael Erman in New York; Editing by Leslie Adler)

US CDC advisers weigh use of GSK, Pfizer RSV vaccines in older adults

June 21 (Reuters) - A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.

GSK unveils positive trial results for vaccine against RSV

(Sharecast News) - GSK unveiled unveiled successful third phase clinical trial results for its Arexvy vaccine against respiratory syncytial virus in older adults.

TOP NEWS: GSK reports positive data for RSV Arexvy vaccine

(Alliance News) - GSK PLC on Wednesday reported positive data for Arexvy, its respiratory syncytial virus vaccine for older adults.

Miners, oil drag London stocks lower after modest China rate cut

Miners down as metal prices fall on strong dollar, China worries

*

Lab crunch: British science has nowhere to go

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.